Skip To Main Content
Demin Shi on Muck Rack

Demin Shi

As seen in: PLOS ONE
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Demin

Contact Demin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer

|
By Demin Shi, Xueyan Liang, Lingyuan Chen
| paperity.org
PLOS ONE, Aug 2023 Objective The clinical efficacy and safety profile of trastuzumab deruxtecan (T-DXd) have been demonstrated in previously treated patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer (BC). It is, however, necessary to evaluate the value of T-DXd considering both its clinical efficacy and its cost, given that it is high.
Open in Who Shared Issue with article?

Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer

|
By Xueyan Liang, Guangxi Academy, Lingyuan Chen, Demin Shi
| PLOS ONE
Discussion In this study, we conducted a cost-effectiveness analysis of T-DXd vs chemotherapy for previously treated HER2-low advanced BC, and the results revealed that compared with chemotherapy, the ICERs of T-DXd was $83,892/QALY, $82,808/QALY, and $93,358/QALY in all HER2-Low advanced BC patients (Scenario 1), HER2+ advanced BC patients (Scenario 2) and HER2- advanced BC patients (Scenario 3), respectively. Even the highest ICER value remains below the threshold for WTP of $100,000/QALY.
Open in Who Shared Issue with article?
See all 2 articles